Exposure-Response Modeling in Heart Failure: Scientific Foundations, Clinical Applications, and Future Directions

Abstract

Exposure-response modeling plays a pivotal role in the advancement of heart failure (HF) pharmacotherapy, providing quantitative frameworks to link drug concentrations (exposure) with therapeutic and adverse clinical outcomes (response). With the growing complexity of HF management and the introduction of novel agents, robust exposure-response relationships inform optimal dosing, individualize therapy, and guide clinical trial design. This review synthesizes current evidence on the application of exposure-response modeling in HF, explores its clinical significance, and highlights emerging directions that promise to further refine patient care in this high-burden condition.

Introduction

Heart failure remains a leading cause of morbidity and mortality worldwide, with evolving treatment paradigms demanding precision and individualization. The application of exposure-response (E-R) modeling in heart failure pharmacotherapy has gained momentum, bridging pharmacokinetics (PK) and pharmacodynamics (PD) to optimize therapeutic outcomes. By quantitatively describing the relationship between systemic drug exposure and clinical response, E-R modeling enables evidence-based dosing strategies, risk mitigation, and informed regulatory decisions. This article reviews the principles, clinical relevance, and future prospects of E-R modeling in heart failure, aiming to equip clinicians and researchers with a comprehensive understanding of its utility.

Epidemiology / Disease Burden

Heart failure affects over 64 million people globally, with an increasing prevalence due to aging populations and improved survival from acute cardiovascular events. The disease imposes significant healthcare and economic burdens, accounting for high rates of hospitalization and mortality. Despite major therapeutic advances, five-year survival rates remain comparable to some malignancies. The complexity of HF pathophysiology, heterogeneity in patient profiles, and frequent polypharmacy underscore the need for individualized, data-driven treatment approaches, where exposure-response modeling can address critical gaps in optimizing therapy and improving outcomes.

Pathophysiology

HF is characterized by impaired ventricular function, neurohormonal activation, and maladaptive remodeling. Underlying mechanisms include altered myocardial contractility, increased afterload, fluid retention, and chronic activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system. These pathophysiological processes create a dynamic milieu where drug effects are modulated by changing cardiac output, organ perfusion, and drug clearance. Exposure-response modeling captures these complexities by integrating PK/PD variability, allowing for mechanistic insight into how disease states influence drug efficacy and safety profiles.

Risk Factors

Traditional risk factors for HF include hypertension, ischemic heart disease, diabetes mellitus, obesity, and valvular dysfunction. Nonmodifiable factors such as age, genetic predisposition, and sex also play roles. Comorbidities like chronic kidney disease and atrial fibrillation further complicate management. These risk factors influence not only disease progression but also drug disposition and response, highlighting the importance of exposure-response analysis to tailor pharmacotherapy considering interindividual variability.

Clinical Features

Patients with HF present with symptoms of volume overload (dyspnea, orthopnea, edema), reduced exercise tolerance, and signs of hypoperfusion (fatigue, confusion). Physical examination may reveal elevated jugular venous pressure, pulmonary rales, and peripheral edema. The heterogeneous clinical phenotype, ranging from HF with reduced ejection fraction (HFrEF) to HF with preserved ejection fraction (HFpEF), necessitates individualized therapeutic strategies, which can be refined by E-R modeling to optimize response while minimizing toxicity.

Diagnosis

Diagnosis of HF relies on clinical assessment, supported by imaging (echocardiography), biomarker analysis (natriuretic peptides), and functional testing. Accurate assessment of disease severity and etiology informs treatment selection and risk stratification. Exposure-response modeling can be integrated into diagnostic algorithms, particularly in monitoring therapeutic drug levels (e.g., digoxin) or predicting responses to newer agents based on patient-specific PK/PD profiles.

Treatment & Management

Standard HF management includes RAAS inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and, more recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors. Device-based therapies and advanced interventions (e.g., cardiac resynchronization, transplantation) are considered in select populations. E-R modeling has been instrumental in defining optimal dose ranges, titration algorithms, and therapeutic drug monitoring approaches, particularly for drugs with narrow therapeutic windows or significant variability in exposure, such as digoxin and sacubitril/valsartan.

Recent Advances / Emerging Therapies

Recent years have witnessed the introduction of novel drug classes, including SGLT2 inhibitors and angiotensin receptor-neprilysin inhibitors (ARNIs), which have demonstrated robust benefits in HF outcomes. Exposure-response analyses from pivotal trials have informed dosing recommendations and identified patient subgroups with enhanced benefit-risk profiles. Additionally, model-informed drug development (MIDD) leveraging population PK/PD modeling, Bayesian forecasting, and machine learning is revolutionizing the way new therapies are evaluated, dosed, and monitored in clinical practice.

Guideline Recommendations

Contemporary HF guidelines increasingly recognize the value of quantitative approaches, including E-R modeling, in guiding therapy. Recommendations emphasize individualized dosing, especially in the context of comorbidities, polypharmacy, and organ dysfunction. Regulatory agencies such as the FDA and EMA advocate for the use of E-R modeling in drug approval processes, dose optimization, and post-marketing surveillance, underscoring its clinical and translational significance.

Conclusion

Exposure-response modeling is integral to modern heart failure therapeutics, offering mechanistic, quantitative, and clinically actionable insights that enhance the precision of care. By systematically linking drug exposure to clinical outcomes, E-R modeling supports evidence-based dose selection, risk mitigation, and the rational development of emerging therapies. Ongoing advances in computational methods and real-world data integration promise to further individualize HF management, ultimately improving patient outcomes in this challenging condition.